Book Value per Share: Ascendis Pharma AS (ASND)

Graphic logo of Ascendis Pharma A/S (ASND)

Scaling the portfolio of Ascendis Pharma A/S (ASND) appears risky, yet the projected book value per share confirms asset stability. The parameter value stands at 24.88, proving the effective monetization of its unique drug delivery system. The biotech's revenues are based on insurance fund payments for the treatment of rare endocrine pathologies, ensuring steady capital growth for the issuer.

Ascendis Pharma AS (ASND): Share Book Value from 07/04/2022 to 10/27/2026

ascendispharma.com - analytical breakdowns and key metrics (ASND)

- price and consensus price forecast:
Price Chart Ascendis Pharma Inc.|ASND - Broker Consensus Forecast
- market capitalization data:
Market Capitalization Ascendis Pharma A/S|ASND - Business Value
- book capitalization data:
Net Assets per Single Share Ascendis Pharma|ASND - Net Asset Value|Market Capitalization to Book Value Ratio ascendispharma.com|ASND - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Ascendis Pharma A/S|ASND - Long-Term Debt to Capital|Short-Term Debt to Equity Ascendis Pharma|ASND - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Ascendis Pharma A/S
Fundamental company valuation:Ascendis Pharma Inc. - ASND
Manufactured products of Ascendis Pharma

Professional capital evaluates the issuer through the prism of the real value of its net assets. This indicator is calculated as the difference between total equity and liabilities, divided by the number of shares. By analyzing the trend in book value per share, an investor sees the actual volume of equity. For Ascendis Pharma A/S (ASND), this reflects the efficiency of investments in prolonged therapies. Steady growth in this metric confirms financial stability prior to scaling production.

Competitors of Ascendis Pharma A/S (ASND)

Madrigal Pharma (MDGL) - Net Assets per Single Share|CORT - Equity per Share|Book Value per Share Rhythm Pharmaceuticals|AKRO (akerotx.com) - Equity per Share|Net Assets per Single Share Metsera MTSR|Share Book Value MoonLake Immunotherapeutics AG|Crinetics Pharma (CRNX) - Book Value per Share|Accounting Value of a Share NewAmsterdam Pharma Corp (NAMS)|Book Value per Share SLNO (Soleno Therapeutics)|amicusrx.com - Book Value per Share|Net Assets per Single Share 89bio (ETNB)|AGIO: Accounting Value of a Share|GPCR (Structure Pharma) - Net Assets per Single Share|MiMedx Corp (MDXG) - Accounting Value per Share|RZLT (Rezolute, Inc.) - Book Value per Share|Book Value per Share lexpharma.com (LXRX)|MBX Biosciences (MBX) - Accounting Value per Share|Accounting Value of a Share ALT (Altimmune Inc)|Aardvark Therapeutics Corp - Net Assets per Single Share|Accounting Value per Share Sagimet Biosciences Inc SGMT|BIOA (BioAge Labs, Inc.) - Book Value per Share|biomeafusion.com (BMEA) - Net Asset Value per Share|QNCX - Accounting Value per Share|Fractyl Health Inc. (GUTS) - Book Price of a Share|VTVT (vTv Therapeutics, Inc.) - Book Value per Share|Book Value per Share Agape ATP Corp.|Book Value per Share Pluri Inc. (PLUR)|Net Assets per Single Share SYBX (synlogictx.com)|LPCN: Net Assets per Single Share|Matinas BioPharma Holdings, Inc. - Net Asset Value per Share|SPRB - Net Assets per Single Share|GLTO - Net Assets per Single Share|Carmell Corporation - Book Value per Share|LUMO (lumos-pharma.com) - Net Assets per Share|ONVO: Net Assets per Single Share|Net Assets per Share RDUS